Tego Science, Inc. Logo

Tego Science, Inc.

Develops and commercializes cell therapies for regenerative medicine.

191420 | KO

Overview

Corporate Details

ISIN(s):
KR7191420009
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙8로 93 (마곡동, 테고사이언스), 서울특별시

Description

Tego Science, Inc. is a biopharmaceutical company specializing in the development and commercialization of cell therapies for regenerative medicine. The company leverages proprietary, advanced cell culture technology for the mass production of human epithelial cells. Its portfolio of approved products includes Holoderm®, an autologous cultured epidermis for severe burns; Kaloderm®, an allogeneic cell therapy for burns and diabetic foot ulcers; and Rosmir®, an autologous fibroblast treatment for wrinkles. In addition to its therapeutic products, Tego Science provides Neoderm®, a 3D cultured skin model used as an alternative to animal testing, and offers CDMO services. The company's clinical pipeline features TPX-115, a first-in-class allogeneic fibroblast-based therapy for treating rotator cuff tears, currently in late-stage clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-11-26 00:00
기업설명회(IR)개최
Korean 6.9 KB
2021-11-15 00:00
분기보고서 (2021.09)
Korean 819.5 KB
2021-11-08 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.2 KB
2021-11-04 00:00
기업설명회(IR)개최
Korean 6.8 KB
2021-10-29 00:00
단일판매ㆍ공급계약체결
Korean 9.4 KB
2021-09-23 00:00
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Korean 55.4 KB
2021-09-15 00:00
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Korean 55.4 KB
2021-08-23 00:00
기업설명회(IR)개최
Korean 6.8 KB
2021-08-13 00:00
반기보고서 (2021.06)
Korean 844.6 KB
2021-07-30 00:00
기타경영사항(특허권취득)(자율공시)
Korean 4.9 KB
2021-06-25 00:00
기업설명회(IR)개최
Korean 6.8 KB
2021-05-14 00:00
분기보고서 (2021.03)
Korean 789.7 KB
2021-05-10 00:00
기타경영사항(특허권취득)(자율공시)(케모카인을 유효성분으로 포함하는 피부개선용 조성물)
Korean 5.1 KB
2021-03-31 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.5 KB
2021-03-31 00:00
주식등의대량보유상황보고서(일반)
Korean 94.3 KB

Automate Your Workflow. Get a real-time feed of all Tego Science, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tego Science, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tego Science, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.